Inactive

RE-SOLICITATION NOTICE – NOTICE OF INTENT NOI-NIAID-2157753 NAICS – 325413 This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of ... RE-SOLICITATION NOTICE – NOTICE OF INTENT NOI-NIAID-2157753 NAICS – 325413 This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Becton, Dickinson and Company to procure BD brand name reagents for COVID-19 and HIV research. The National Institutes of Health (NIH) Vaccine Research Center (VRC) is developing vaccines for SARS-CoV-2, HIV-1 and other viruses. Production of various wild-type and mutant viral proteins and anti-viral antibodies is critical in vaccine development. This requirement is for reagents for COVID-19 and HIV research. These reagents are used to examine blood and tissue derived immune cell subtypes and the cytokines they produce in animal studies where specimens have been immunized against and/or subsequently infected with COVID-19 OR SHIV (the non-human primate equivalent of human immunodeficiency virus). The reagents required on this acquisition have been selected based on their continued use in a qualified assay that relies on stringent reproducibility across experiments and users. The reagents have been titrated to ensure correct amount per assay, as well as the specific clone or isotype that yields the most consistent results. Deviation from these qualified reagents will require substantial person-hours to recertify new reagents and will also forfeit consistency with previous studies related to the ongoing research. Development of panels for immunophenotyping by high-dimensional flow cytometry requires extensive and sophisticated testing of reagents. The VRC has tested several of these reagents from different companies and selected the best performing reagents. Often, the selection of reagents differs among vendors and many fluorochromes and reagents are only available from BD Biosciences. Based on these facts must obtain these reagents from BD Biosciences. The National Institute of Allergy and Infectious Diseases (NIAID) has a requirement for the following Becton, Dickinson & Co (BD Biosciences) Brand Name Supplies: 560493 Hu IL-21 Alexa 647 3A3-N2.1 100Tst QTY 20 EA 563580 Hu IL-13 BV421 JES10-5A2 50Tst QTY 50 EA 566361 Hu IL-2 BV750 MQ1-17H12 50ug QTY 30 EA 554512 Hu TNF FITC MAb11 100ug Flow Assay QTY 30 EA Shipping and Handling Place of Performance: NIH, 9 West Watkins Mill Road, Gaithersburg, MD 20878, United States. FOB: Destination The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-2157753 to Dana Monroe at dana.monroe@nih.gov by 5:00pm EST January 23, 2023. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.